Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature
Immune checkpoint inhibitor (ICI) is an up-to-date therapy for cancer with a promising efficacy, but it may cause unique immune-related adverse events (irAEs). Although irAEs could affect any organ, irAEs-induced whole urinary tract expansion was rarely reported. Herein, we reported a 27-year-old ma...
Main Authors: | Qihao Zhou, Zhiquan Qin, Peiyuan Yan, Qunjiang Wang, Jing Qu, Yun Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-10-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1226993/full |
Similar Items
-
Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature
by: Jiaxiang Ji, et al.
Published: (2024-12-01) -
Case Report: A Case of Sintilimab-Induced Cystitis/Ureteritis and Review of Sintilimab-Related Adverse Events
by: Lingfang Tu, et al.
Published: (2021-12-01) -
Successful treatment of BK virus‐associated severe hemorrhagic cystitis with bilateral single‐J ureteral stenting
by: Akira Fujita, et al.
Published: (2022-07-01) -
Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
by: Liman Huo, et al.
Published: (2023-10-01) -
Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers
by: Xiaojing Zheng, et al.
Published: (2023-02-01)